类风湿关节炎一级亲属非临床筛查自身抗体阳性后进展为炎症性关节炎的相关因素
在1780名类风湿关节炎(RA)患者的一级亲属中筛查抗CCP抗体和类风湿因子同型自身抗体,304人(17.1%)自身抗体阳性。中位随访4.4年,20人(15.3%)进展为炎症性关节炎;抗CCP抗体≥2倍标准 cut-off 与抗体持续阳性及未来炎症性关节炎风险约4倍升高相关。
要点
- 抗CCP抗体≥2倍标准 cut-off 与抗体持续阳性风险升高13倍相关。
- 抗CCP抗体≥2倍或最佳 cut-off 者5年内炎症性关节炎发生率分别为32%和26%。
核心结论
- 非临床场景下自身抗体筛查可识别RA相关自身抗体阳性个体及未来炎症性关节炎高风险水平与组合。
研究设计与样本
- 对1780名RA患者一级亲属筛查血清抗CCP抗体和类风湿因子同型自身抗体,评估抗体组合及高滴度抗体对持续阳性和炎症性关节炎的预测作用。
主要发现
- 304名(17.1%)受试者自身抗体阳性,其中131名无炎症性关节炎且有至少一次随访。
- 中位随访4.4年(IQR 2.2-7.2),20名(15.3%)受试者发生炎症性关节炎。
- 抗CCP抗体≥2倍标准 cut-off 与自身抗体持续阳性风险升高13倍相关。
- 抗CCP抗体≥2倍或≥最佳 cut-off 者5年内炎症性关节炎发生率分别为32%和26%,未来炎症性关节炎风险约升高4倍(HR 4.09和HR 3.95,p<0.01)。
关键数值与推荐
- 抗CCP抗体≥2倍标准 cut-off 与自身抗体持续阳性风险升高13倍相关。
- 抗CCP抗体≥2倍标准 cut-off 者5年内炎症性关节炎发生率为32%。
- 抗CCP抗体≥最佳 cut-off 者5年内炎症性关节炎发生率为26%。
- 抗CCP抗体≥2倍或≥最佳 cut-off 对未来炎症性关节炎的HR分别为4.09和3.95(p<0.01)。
临床怎么用
- 对RA一级亲属中自身抗体阳性个体应监测炎症性关节炎的发生。
- 在风险人群中采用类似自身抗体检测方法可能识别RA预防研究的候选对象。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Little is known about the likelihood of developing inflammatory arthritis (IA) in individuals who screen autoantibody positive (aAb+) in a non-clinical research setting. METHODS: We screened for serum cyclic citrullinated peptide antibody (anti-CCP) and rheumatoid factor isotype aAbs in subjects who were at increased risk for rheumatoid arthritis (RA) because they are a first-degree relative of an individual with classified RA (n=1780). We evaluated combinations of aAbs and high titre aAbs, as defined by 2-times (2 x) the standard cut-off and an optimal cut-off, as predictors of our two outcomes, aAb+ persistence and incident IA. RESULTS: 304 subjects (17.1%) tested aAb+; of those, 131 were IA-free and had at least one follow-up visit. Sixty-four per cent of these tested aAb+ again on their next visit. Anti-CCP+ at levels ≥2 x the standard cut-off was associated with 13-fold higher likelihood of aAb +persistence. During a median of 4.4 years (IQR: 2.2-7.2), 20 subjects (15.3%) developed IA. Among subjects that screened anti-CCP+ at ≥ 2 x or ≥an optimal cut-off, 32% and 26% had developed IA within 5 years, respectively. Both anti-CCP cut-offs conferred an approximate fourfold increased risk of future IA (HR 4.09 and HR 3.95, p<0.01). CONCLUSIONS: These findings support that aAb screening in a non-clinical setting can identify RA-related aAb+ individuals, as well as levels and combinations of aAbs that are associated with higher risk for future IA. Monitoring for the development of IA in aAb+ individuals and similar aAb testing approaches in at-risk populations may identify candidates for prevention studies in RA.
引用
- Bemis EA, Demoruelle MK, Seifert JA, et al. Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting. Ann Rheum Dis. 2020. PMID: 32928740. doi:10.1136/annrheumdis-2020-217066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。